loading
Acadia Pharmaceuticals Inc stock is traded at $25.74, with a volume of 3.38M. It is up +3.85% in the last 24 hours and up +14.05% over the past month. Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
See More
Previous Close:
$24.79
Open:
$24.97
24h Volume:
3.38M
Relative Volume:
1.64
Market Cap:
$4.34B
Revenue:
$890.53M
Net Income/Loss:
$30.57M
P/E Ratio:
143.00
EPS:
0.18
Net Cash Flow:
$80.53M
1W Performance:
+1.62%
1M Performance:
+14.05%
6M Performance:
+29.02%
1Y Performance:
+64.16%
1-Day Range:
Value
$24.90
$25.81
1-Week Range:
Value
$24.46
$25.81
52-Week Range:
Value
$13.40
$25.88

Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile

Name
Name
Acadia Pharmaceuticals Inc
Name
Phone
858-558-2871
Name
Address
12830 EL CAMINO REAL, SAN DIEGO
Name
Employee
654
Name
Twitter
@acadiapharma
Name
Next Earnings Date
2024-11-06
Name
Latest SEC Filings
Name
ACAD's Discussions on Twitter

Compare ACAD with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
ACAD
Acadia Pharmaceuticals Inc
25.74 4.23B 890.53M 30.57M 80.53M 0.18
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
395.12 99.96B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
589.48 60.83B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
454.38 59.89B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
660.00 40.47B 3.06B 1.28B 447.35M 21.30
Biotechnology icon
ONC
Beone Medicines Ltd Adr
313.67 37.96B 3.81B -644.79M -669.77M -6.24

Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades

Date Action Analyst Rating Change
May-21-25 Upgrade Deutsche Bank Hold → Buy
Feb-11-25 Initiated Deutsche Bank Hold
Jan-03-25 Downgrade Guggenheim Buy → Neutral
Oct-10-24 Resumed Raymond James Mkt Perform
Aug-07-24 Downgrade Morgan Stanley Overweight → Equal-Weight
Jun-27-24 Initiated BMO Capital Markets Outperform
Mar-12-24 Downgrade Mizuho Buy → Neutral
Mar-12-24 Reiterated Needham Buy
Jan-30-24 Initiated Robert W. Baird Outperform
Jan-24-24 Upgrade Needham Hold → Buy
Dec-19-23 Upgrade Morgan Stanley Equal-Weight → Overweight
Dec-14-23 Downgrade Deutsche Bank Buy → Hold
Dec-13-23 Initiated Citigroup Buy
Dec-12-23 Initiated Deutsche Bank Buy
Nov-06-23 Upgrade Mizuho Neutral → Buy
Oct-17-23 Initiated UBS Buy
Oct-10-23 Upgrade JP Morgan Neutral → Overweight
Jan-03-23 Upgrade Guggenheim Neutral → Buy
Nov-04-22 Downgrade Goldman Neutral → Sell
Nov-01-22 Initiated Loop Capital Hold
Aug-08-22 Downgrade Citigroup Buy → Neutral
Aug-05-22 Downgrade Citigroup Buy → Neutral
Jun-21-22 Downgrade Jefferies Buy → Underperform
Jun-16-22 Upgrade Jefferies Hold → Buy
Mar-16-22 Upgrade Canaccord Genuity Hold → Buy
Feb-09-22 Upgrade H.C. Wainwright Neutral → Buy
Jan-05-22 Upgrade Citigroup Neutral → Buy
Dec-21-21 Downgrade Guggenheim Buy → Neutral
Nov-01-21 Upgrade Guggenheim Neutral → Buy
Oct-14-21 Downgrade Morgan Stanley Overweight → Equal-Weight
Sep-23-21 Resumed Needham Hold
Jun-10-21 Initiated Berenberg Hold
Apr-07-21 Downgrade H.C. Wainwright Buy → Neutral
Apr-06-21 Downgrade Canaccord Genuity Buy → Hold
Apr-06-21 Downgrade Goldman Buy → Neutral
Apr-06-21 Downgrade Jefferies Buy → Hold
Apr-06-21 Downgrade Mizuho Buy → Neutral
Apr-05-21 Downgrade Raymond James Outperform → Mkt Perform
Mar-10-21 Downgrade BofA Securities Buy → Neutral
Mar-09-21 Downgrade Citigroup Buy → Neutral
Mar-09-21 Downgrade Guggenheim Buy → Neutral
Mar-09-21 Reiterated H.C. Wainwright Buy
Mar-09-21 Downgrade Raymond James Strong Buy → Outperform
Mar-09-21 Downgrade Stifel Buy → Hold
Dec-16-20 Initiated Mizuho Buy
Nov-16-20 Upgrade Raymond James Outperform → Strong Buy
Aug-25-20 Initiated Raymond James Outperform
Aug-20-20 Initiated Morgan Stanley Overweight
Jul-07-20 Upgrade Stifel Hold → Buy
Apr-16-20 Initiated Jefferies Buy
Mar-31-20 Upgrade Goldman Neutral → Buy
Mar-06-20 Initiated Citigroup Buy
Dec-16-19 Initiated Guggenheim Buy
Oct-24-19 Initiated Oppenheimer Perform
Oct-01-19 Initiated RBC Capital Mkts Outperform
Sep-13-19 Upgrade SVB Leerink Mkt Perform → Outperform
Sep-10-19 Upgrade Canaccord Genuity Hold → Buy
Jul-23-19 Reiterated Needham Buy
Dec-10-18 Initiated Canaccord Genuity Hold
Sep-21-18 Upgrade Piper Jaffray Neutral → Overweight
Aug-09-18 Reiterated Stifel Hold
Aug-07-18 Initiated Stifel Hold
Aug-06-18 Downgrade Piper Jaffray Overweight → Neutral
Oct-06-17 Resumed Goldman Neutral
View All

Acadia Pharmaceuticals Inc Stock (ACAD) Latest News

pulisher
Aug 19, 2025

Acadia Pharma EVP Schneyer sells $554k in stock By Investing.com - Investing.com South Africa

Aug 19, 2025
pulisher
Aug 19, 2025

Acadia Pharma EVP Schneyer sells $554k in stock - Investing.com

Aug 19, 2025
pulisher
Aug 17, 2025

What makes ACADIA Pharmaceuticals Inc. stock price move sharplyPortfolio Update Report & Real-Time Market Sentiment Reports - beatles.ru

Aug 17, 2025
pulisher
Aug 16, 2025

Will ACADIA Pharmaceuticals Inc. Recover After Recent Decline2025 Top Gainers & Verified Momentum Watchlists - newsyoung.net

Aug 16, 2025
pulisher
Aug 15, 2025

High Growth Tech Stocks To Watch In The US August 2025 - simplywall.st

Aug 15, 2025
pulisher
Aug 14, 2025

ACADIA Pharmaceuticals’ SWOT analysis: stock poised for growth amid challenges - Investing.com

Aug 14, 2025
pulisher
Aug 14, 2025

Statutory Earnings May Not Be The Best Way To Understand ACADIA Pharmaceuticals' (NASDAQ:ACAD) True Position - 富途牛牛

Aug 14, 2025
pulisher
Aug 14, 2025

Shareholders In ACADIA Pharmaceuticals (NASDAQ:ACAD) Should Look Beyond Earnings For The Full Story - Yahoo Finance

Aug 14, 2025
pulisher
Aug 13, 2025

Mizuho lowers Acadia Pharmaceuticals stock price target to $22 from $32 - Investing.com Nigeria

Aug 13, 2025
pulisher
Aug 13, 2025

Acadia Pharmaceuticals (ACAD) Tops Q2 Earnings and Revenue Estimates - MSN

Aug 13, 2025
pulisher
Aug 13, 2025

Acadia Pharmaceuticals at Canaccord Conference: Strategic Growth and Innovation By Investing.com - Investing.com Nigeria

Aug 13, 2025
pulisher
Aug 13, 2025

Acadia Pharmaceuticals at Canaccord Conference: Strategic Growth and Innovation - Investing.com

Aug 13, 2025
pulisher
Aug 12, 2025

Acadia Pharmaceuticals stock hits 52-week high at 25.24 USD By Investing.com - Investing.com India

Aug 12, 2025
pulisher
Aug 12, 2025

Acadia Pharmaceuticals stock hits 52-week high at 25.24 USD - Investing.com

Aug 12, 2025
pulisher
Aug 12, 2025

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 11, 2025 - BioSpace

Aug 12, 2025
pulisher
Aug 11, 2025

ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock Price Expected to Rise, Mizuho Analyst Says - MarketBeat

Aug 11, 2025
pulisher
Aug 11, 2025

JMP Securities Boosts ACADIA Pharmaceuticals (NASDAQ:ACAD) Price Target to $38.00 - MarketBeat

Aug 11, 2025
pulisher
Aug 11, 2025

The Goldman Sachs Group Issues Positive Forecast for ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock Price - MarketBeat

Aug 11, 2025
pulisher
Aug 10, 2025

Buy Rating on ACADIA Pharmaceuticals Driven by Daybue’s Sales Growth and Market Expansion - TipRanks

Aug 10, 2025
pulisher
Aug 09, 2025

UBS Raises Price Target for ACADIA Pharmaceuticals to $36 - AInvest

Aug 09, 2025
pulisher
Aug 09, 2025

Results: ACADIA Pharmaceuticals Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts - simplywall.st

Aug 09, 2025
pulisher
Aug 09, 2025

Results: ACADIA Pharmaceuticals Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates - Yahoo Finance

Aug 09, 2025
pulisher
Aug 09, 2025

Acadia Q2 Earnings Beat, Nuplazid & Daybue Sales Drive Revenue Growth - MSN

Aug 09, 2025
pulisher
Aug 08, 2025

Acadia Pharmaceuticals shares rise 1.05% intraday after UBS raised price target to $36. - AInvest

Aug 08, 2025
pulisher
Aug 08, 2025

RBC Capital Remains a Buy on ACADIA Pharmaceuticals (ACAD) - The Globe and Mail

Aug 08, 2025
pulisher
Aug 08, 2025

A Quick Look at Today's Ratings for ACADIA Pharmaceuticals(ACAD.US), With a Forecast Between $17 to $40 - 富途牛牛

Aug 08, 2025
pulisher
Aug 08, 2025

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q2 2025 Earnings Call Transcript - Insider Monkey

Aug 08, 2025
pulisher
Aug 08, 2025

Earnings Beat: ACADIA Pharmaceuticals Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models - 富途牛牛

Aug 08, 2025
pulisher
Aug 08, 2025

ACADIA Pharmaceuticals Second Quarter 2025 Earnings: EPS Beats Expectations - Yahoo Finance

Aug 08, 2025
pulisher
Aug 08, 2025

Acadia Pharmaceuticals (ACAD) Shares Surge 3.07% to New Peak on Q2 Earnings, Patent Wins - AInvest

Aug 08, 2025
pulisher
Aug 08, 2025

ACADIA Pharmaceuticals: Strong Growth and Undervalued Pipeline Support Buy Rating - TipRanks

Aug 08, 2025
pulisher
Aug 08, 2025

Why ACADIA Pharmaceuticals Inc. (ACAD) Skyrocketed on Friday - MSN

Aug 08, 2025
pulisher
Aug 08, 2025

Acadia Pharmaceuticals Reports Strong Q2 2025 Growth - The Globe and Mail

Aug 08, 2025
pulisher
Aug 07, 2025

ACADIA Pharmaceuticals Reports Strong Q2 2025 Earnings - TipRanks

Aug 07, 2025
pulisher
Aug 07, 2025

Acadia Pharmaceuticals stock price target raised to $24 from $18 at Stifel - Investing.com Canada

Aug 07, 2025
pulisher
Aug 07, 2025

Mizuho Maintains Neutral Rating, Raises Price Target for ACADIA Pharmaceuticals to $24 - AInvest

Aug 07, 2025
pulisher
Aug 07, 2025

A Quick Look at Today's Ratings for ACADIA Pharmaceuticals(ACAD.US), With a Forecast Between $17 to $38 - 富途牛牛

Aug 07, 2025
pulisher
Aug 07, 2025

Mizuho raises Acadia Pharmaceuticals stock price target on solid earnings By Investing.com - Investing.com Canada

Aug 07, 2025
pulisher
Aug 07, 2025

Mizuho raises Acadia Pharmaceuticals stock price target on solid earnings - Investing.com

Aug 07, 2025
pulisher
Aug 07, 2025

Acadia Pharmaceuticals price target raised to $38 from $37 at Citizens JMP - TipRanks

Aug 07, 2025
pulisher
Aug 07, 2025

Acadia Pharmaceuticals price target raised to $27 from $23 at BofA - TipRanks

Aug 07, 2025
pulisher
Aug 07, 2025

Acadia Pharmaceuticals Beats Q2 Earnings ForecastsNews and Statistics - IndexBox

Aug 07, 2025
pulisher
Aug 07, 2025

Acadia: Q2 Earnings Snapshot - New Haven Register

Aug 07, 2025
pulisher
Aug 07, 2025

Acadia Pharmaceuticals stock price target raised to $38 from $37 at Citizens JMP - Investing.com Australia

Aug 07, 2025
pulisher
Aug 07, 2025

Acadia Pharmaceuticals shares rise 2.10% premarket after FDA approves expanded indication for AJOVY. - AInvest

Aug 07, 2025
pulisher
Aug 07, 2025

Acadia Pharmaceuticals Raises Guidance As Sales Climb In Q2 - Finimize

Aug 07, 2025
pulisher
Aug 07, 2025

Earnings call transcript: ACADIA Pharmaceuticals Q2 2025 beats forecasts By Investing.com - Investing.com Canada

Aug 07, 2025
pulisher
Aug 07, 2025

Instagram Rolls Out New Features for Personalized Content Discovery and Sharing - AInvest

Aug 07, 2025
pulisher
Aug 07, 2025

ACADIA Pharmaceuticals Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:ACAD) - Seeking Alpha

Aug 07, 2025

Acadia Pharmaceuticals Inc Stock (ACAD) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$24.65
price up icon 0.94%
$85.04
price down icon 1.72%
$26.20
price up icon 0.73%
$110.88
price up icon 0.10%
$131.88
price down icon 0.54%
biotechnology ONC
$313.67
price down icon 0.10%
Cap:     |  Volume (24h):